Notably, the most common non–FDA-approved indications were cancers with limited targeted therapies available: pancreatic cancer for FGFR2 fusions (prevalence of 0.5%) and prostate cancer for FGFR3 and NRG1 fusions (combined prevalence of 0.4%). This evidence concerns the gene FGFR2 and familial pancreatic carcinoma.